Prime Medicine, Inc. (PRME) Stock Analysis & Investment Frameworks
Prime Medicine, Inc. (PRME) stock analysis on Invetso. Review Prime Medicine, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Prime Medicine, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Prime Medicine, Inc. Key Financial Metrics
- Market Cap: $843.40M
- Revenue: $4.63M
- ROE: -188.27%
- ROIC: -86.83%
- Dividend Yield: N/A
About Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.